3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Neoplasms
6
Breast Neoplasms
5
Myeloproliferative Disorders
3
Melanoma
3
Lung Neoplasms
3
Triple Negative Breast Neoplasms
2
Skin Neoplasms
2
Leukemia, Myeloid, Acute
2
Head and Neck Neoplasms
2
von Hippel-Lindau Disease
1
Thrombosis
1
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Rectal Neoplasms
1
Pyruvate Kinase Deficiency of Red Cells
1
Precancerous Conditions
1
Pancreatic Cyst
1
Neuroendocrine Tumors
1
Neoplasm, Residual
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Myelitis, Transverse
1
Myasthenia Gravis
1
Multiple Sclerosis
1
Metastatic Castration-resistant Prostate Cancer
1
Marijuana Abuse
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell
1
Interventions
pembrolizumab
2
tremelimumab
1
poly ICLC
1
lenvatinib
1
durvalumab
1
balstilimab
1
Peptides
1
Pemetrexed
1
Carboplatin
1
Blood Specimen Collection
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Diabetes Mellitus, Insulin-Dependent, 12
×
Blood Specimen Collection
×
30 days
×
Clear all
NCT04253080
2026-05-20
ENZYMELA
Assistance Publique - Hôpitaux de Paris
Phase NA
Completed
127 enrolled